Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ActivBiotics Inc.

Latest From ActivBiotics Inc.

Inhibikase Therapeutics elects Steven Gilman to board

Inhibikase Therapeutics, a creator of anti-infective therapies, has elected Dr Steven Gilman to its board of directors. Dr Gilman currently serves as executive vice-president, R&D and chief scientific officer at Cubist Pharmaceuticals. Prior to this, he was chairman, president and CEO of ActivBiotics.

As Drug-Resistant Microbes Rise, Antibiotic Start-Ups Need Savvy Investors

VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Merlin Technologies Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ActivBiotics Inc.
  • Senior Management
  • James L Warren, CFO
    Andrew Stenlicht, VP, Clinical Dev.
    Glenn Kazo, CBO
  • Contact Info
  • ActivBiotics Inc.
    Phone: (781) 372-4814
    128 Spring St.
    Lexington, MA 02421